- EASL results: HepC developers seeking shorter treatments
- Achillion, Regulus chase shorter HCV regimens, but can they beat Gilead?
- AASLD data confirm Gilead as ultimate hep C champion
- Gilead seeks FDA nod for new HIV quad
ANALYSIS Other Informa Analysis
- INTERVIEW: Champions Oncology champions personalized tumor models
- PROFILE: Getting to know GSK dermatologist David Rubenstein, head to toe